A composition, a kit, and a method of isolating a vesicle from a sample using a compound comprising zwitterion moieties, which may be used to analyze vesicles, and proteins, glycoprotein, lipids, or nucleic acids thereof.

The present invention relates a simple method for evaluating free eukaryotic cell nuclei for biomarkers of DNA damage and/or transcription factor activation, activity, or expression levels and/or epigenetic modifications to chromatin or chromatin-associated factors. The invention also teaches useful strategies for combining nuclear biomarkers into a matrix of endpoints that are capable of elucidating genotoxicants' primary mode of DNA-damaging activity. Kits for conducting methods according to the invention are also described.

The present disclosure provides methods, devices, and kits useful for screening or characterizing extracellular vesicles (e.g., exosomes) by monitoring cell-type specific extracellular vesicle uptake and/or cells' feedback responses.

A method involves recovery an extracellular vesicle from an extracellular vesicle-containing sample. Such a method of recovering the extracellular vesicle may include separating the extracellular vesicle from the extracellular vesicle-containing sample in the presence of a polymer.

The invention relates to a method for determining the florescence of antibodies on exosomes using quality control of the measurement using two different control methods.

This document provides methods and materials for assessing cancer. For example, methods and materials that can be used to determine if a mammal (e.g., a human) having cancer is likely to be responsive to a cancer immunotherapy (e.g., a chimeric T cell therapy) are provided. In some cases, methods and materials for treating a mammal having cancer and identified as being likely to respond to a cancer immunotherapy (e.g., a chimeric T cell therapy) are also provided.

The present description relates to methods for clinically assessing Parkinson's disease in a subject using protein biomarkers of erythrocyte-derived extracellular vesicles (EEV).

The present invention related to a compound for use in prevention or treatment of a neurodegenerative disease associated with the formation of stress granules. The compound is selected from lipoic acid, lipoamide, dihydrolipoic acid, and dihydrolipoamide. The invention further relates to a method of identifying a compound that modulates a characteristic associated with one or more condensates comprising a condensate-associated molecule, comprising: (a) contacting the compound with a cellular composition comprising one or more condensates or a cellular composition capable of forming one or more condensates, and (b) determining the characteristic associated with the one or more condensates. A modulation in the characteristic, as compared to a reference, indicates that the compound modulates the characteristic associated with the one or more condensates.

Provided herein are, inter alia, extracellular products (e.g., vesicles such as microvesicles, e.g., exosomes) produced by renal cells (such as bioactive renal cells, e.g., selected renal cells). Methods of altering components (such as miRNAs or proteins) of vesicles produced by cells, as well as methods of producing vesicles comprising various compounds are also included. Also provided are diagnostic and treatment methods.

The invention relates to method and kits for highly specific isolation of extracellular vesicles (EVs) by targeting at least two EV surface markers. The invention further relates to methods and kits for analyzing EVs and their contents.